AnaptysBio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANAB research report →
About the company
AnaptysBio, Inc. , a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
- CEO
- Daniel Faga
- IPO
- 2017
- Employees
- 104
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $2.73B
- P/E
- -74.61
- P/S
- 11.77
- P/B
- 142.75
- EV/EBITDA
- 47.25
- Div Yield
- 0.00%
- Gross Margin
- 116.42%
- Op Margin
- 17.56%
- Net Margin
- -11.53%
- ROE
- 442.91%
- ROIC
- 14.06%
- Revenue
- $234.60M · 157.01%
- Net Income
- $-13,232,000 · 90.89%
- EPS
- $-0.46 · 91.02%
- Op Income
- $47.90M
- FCF YoY
- 114.45%
- 52W High
- $72.36
- 52W Low
- $11.40
- 50D MA
- $60.00
- 200D MA
- $38.20
- Beta
- 0.38
- Avg Volume
- 674.21K
Get TickerSpark's AI analysis on ANAB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 15, 26 | Schmid John P. | other | 6,030 |
| Jun 15, 26 | Schmid John P. | other | 6,030 |
| Jun 15, 26 | RENTON HOLLINGS | other | 6,030 |
| Jun 15, 26 | RENTON HOLLINGS | other | 6,030 |
| Jun 15, 26 | Orwin John A | other | 6,030 |
| Jun 15, 26 | Orwin John A | other | 6,030 |
| May 11, 26 | Hughes Owen | other | 11,250 |
| May 11, 26 | Hughes Owen | other | 0 |
| May 11, 26 | Murphy Christopher M. | other | 25,765 |
| May 11, 26 | Murphy Christopher M. | other | 0 |
Our ANAB coverage
Recent articles, reports, and earnings notes.
No research on ANAB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ANAB report →Similar companies
Peers in the same neighborhood.